Xultophy 100/3.6 (Novo Nordisk)
Welcome to the PulseAid listing for the Xultophy 100/3.6 drug offered from Novo Nordisk. This Insulin [Chemical/Ingredient],Insulin Analog [EPC],GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [Chemical/Ingredient],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novo Nordisk |
| NON-PROPRIETARY NAME: | (insulin degludec and liraglutide) |
| SUBSTANCE NAME: | INSULIN DEGLUDEC; LIRAGLUTIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Insulin [Chemical/Ingredient],Insulin Analog [EPC],GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [Chemical/Ingredient],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
| ROUTE: | SUBCUTANEOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2016-11-21 |
| END MARKETING DATE: | 0000-00-00 |
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG Details:
| Item Description | Xultophy 100/3.6 from Novo Nordisk |
| LABELER NAME: | Novo Nordisk |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100; 3.6([iU]/mL; mg/mL) |
| START MARKETING DATE: | 2016-11-21 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0169-2911_21335fe4-d395-4501-ac2a-2f20d7520da9 |
| PRODUCT NDC: | 0169-2911 |
| APPLICATION NUMBER: | NDA208583 |
Other INSULIN DEGLUDEC; LIRAGLUTIDE Pharmaceutical Manufacturers / Labelers:
